July 25, 2007 - The Cedara I-Response application from Cedara Software is designed to help evaluate, assess and monitor the effect of cancer therapy over time using data from multiple modalities. Not only does it provide tools for the standard anatomical measurements used for tumor assessment in cancer management and research, Cedara I-Response can also reportedly analyze both PET/CT and MR-based diffusion-weighted imaging (DWI). According to the company, by providing the ability to visualize changes in tumors resulting from cellular and metabolic mechanisms during the course of treatment, Cedara I-Response provides clinically relevant information that potentially could be used to make mid-treatment therapy adjustments in an attempt to improve clinical outcome.
Cedara I-Response also features patented functional Diffusion Map (fDM) technology. This functionality enables physicians to analyze DWI studies to visualize and quantify changes over time in the microscopic motion of water in healthy and diseased tissues. University of Michigan investigators have demonstrated that fDM can identify brain tumor patients who are responding to radiation (plus adjuvant chemotherapy in some cases) after only three weeks of treatment, more than two months earlier than conventional methods. "I-Response could provide a standardized avenue for individualized early treatment response monitoring in oncology patients," said Brian Ross, Ph.D., co-director of the molecular imaging program at the University of Michigan Comprehensive Cancer Center, and professor of Radiology and Biological Chemistry.
I-Response is available to OEMs as a stand-alone workstation, or it can be integrated into existing PACS solutions using Cedara's unique C4 integration platform.*
*The C4-enabled version of I-Response is a works-in-progress.
For more information: www.cedara.com